Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease | MicrobiomeTrials← Back to trialsNCT06976853
Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-05-13Est. Completion: 2028-05
Enrollment target: 60 participants Locations- Cedars-Sinai Medical Center, Beverly Hills, California, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Icahn School of Medicine at Mount Sinai, New York, New York, United States
Other microbiome trials you might be interested in
Inflammatory Bowel Disease
Crohn's Disease (CD) and Ulcerative Colitis (UC), collectively known as inflammatory bowel disease (IBD), are two of the…
Chicago, United StatesEst. completion Sep 1, 2026
Crohn Disease (CD)
This multicenter, randomized, controlled trial aims to evaluate the efficacy and safety of standard-dose tumor necrosis …
Guangzhou, ChinaEst. completion Dec 31, 2028
ENROLLING_BY_INVITATION
Inflammatory Bowel Diseases (IBD)Remission of IBDIn AdultsInflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis)Crohn's Disease (CD)Ulcerative Colitis (UC)
The VIBRANT-IBD study is a pilot, prospective, single-arm feasibility study investigating the effects of non-invasive va…
Gdansk, PolandCompleted Dec 15, 2026